» Articles » PMID: 33088863

Treatment of Femoral Head Osteonecrosis (Stages 2B, 3 Ficat) Through Open Direct Core Decompression by Allograft Impaction and Light Bulb Technique

Overview
Date 2020 Oct 22
PMID 33088863
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Femoral head avascular necrosis is the cause of paralyzing status of youth population. Initial diagnosis is the main element in treating the disease. Bone grafting and core decompression are the approved cures at the early steps of the disease. Hip replacement in a total manner is the common cure in the final stages. The optimal treatment in the intermediate stages is partially disputable. We investigated several patients with femoral head osteonecrosis cured with impacted cancellous allograft and open core decompression using the lightbulb technique.

Methods: A total of 46 patients (58 hips) suffering from femoral head osteonecrosis were evaluated in this cross-sectional study. Patients were classified into two groups: A (stage 2B Ficat) and B (stage 3 Ficat) to be treated with the impaction of cancellous allograft and by open core decompression. Radiographic results, demographic data, and range of hip joint motions were recorded. The patients were assessed through employing the Harris hip score (HHS) and visual analogue scale (VAS) index prior to operation and over five years following surgery. We also studied radiographic alterations of femoral head.

Results: The means of HHS and VAS were developed following the operation. Radiographic outcomes promoted in both groups, however, it was better in group A. 12 (40%) and six (22%) hips (40%) in groups A and B, respectively displayed developed stages following the operation. The hip ROM was enhanced with the mean of 15-20 degrees ().

Conclusion: Open core decompression combined with allograft impaction sounds to be influential in the developing steps of femoral head necrosis and leads to joint discomfort and diminished pain improving ROM of the hip joint and meanwhile procrastinating the worsening of the disease.

Citing Articles

Comparison of the efficacy between Super-Path and Watson-Jones approaches in the management of early femoral head necrosis.

Xu Y, Zeng P Medicine (Baltimore). 2025; 104(4):e41391.

PMID: 39854751 PMC: 11771660. DOI: 10.1097/MD.0000000000041391.


Jack Surgery: Reconstructing Collapsed Femoral Head in Association Research Circulation Osseous Stage III Osteonecrosis: A Series of 13 Cases.

Zhong Y, Gong Y, Lv S, Du W, Liu X, Zhang J Orthop Surg. 2024; 17(2):644-652.

PMID: 39575477 PMC: 11787987. DOI: 10.1111/os.14298.


Comparison of current treatment strategy for osteonecrosis of the femoral head from the perspective of cell therapy.

Wang J, Xu P, Zhou L Front Cell Dev Biol. 2023; 11:995816.

PMID: 37035246 PMC: 10073660. DOI: 10.3389/fcell.2023.995816.

References
1.
Aldridge 3rd J, Urbaniak J . Avascular necrosis of the femoral head: etiology, pathophysiology, classification, and current treatment guidelines. Am J Orthop (Belle Mead NJ). 2004; 33(7):327-32. View

2.
Glimcher M, Kenzora J . The biology of osteonecrosis of the human femoral head and its clinical implications. III. Discussion of the etiology and genesis of the pathological sequelae; commments on treatment. Clin Orthop Relat Res. 1979; (140):273-312. View

3.
Urbaniak J, Coogan P, Gunneson E, Nunley J . Treatment of osteonecrosis of the femoral head with free vascularized fibular grafting. A long-term follow-up study of one hundred and three hips. J Bone Joint Surg Am. 1995; 77(5):681-94. DOI: 10.2106/00004623-199505000-00004. View

4.
Tsai S, Wu P, Chen C, Chiang C, Huang C, Chen T . Etiologies and outcome of osteonecrosis of the femoral head: Etiology and outcome study in a Taiwan population. J Chin Med Assoc. 2015; 79(1):39-45. DOI: 10.1016/j.jcma.2015.07.010. View

5.
Sorich M, Cherian J, McElroy M, Banerjee S, Jones L, Minniti C . Osteonecrosis of the Hip in Hematologic Disease: A Review of Conditions and Treatment Options. J Long Term Eff Med Implants. 2016; 25(4):253-68. DOI: 10.1615/jlongtermeffmedimplants.2015012529. View